歐洲液態切片市場（按最終用戶和國家/地區分類）-分析和預測（2024-2033 年）

預計 2024 年歐洲液態切片市場價值將達到 12.4 億美元。

預計到 2033 年，市場規模將達到 55.8 億美元，在 2024-2033 年預測期內，複合年成長率將達到 18.18%。在歐洲，液態切片是一種新型非侵入性診斷技術，正在徹底改變癌症的檢測和監測。該方法有可能早期發現癌症復發並評估治療的效果，並能夠以微創的方式進行即時監測。癌症發生率不斷上升、研究論文和臨床試驗數量不斷增加是推動液態切片市場成長的一些因素。這些因素導致對液態切片測試和產品的需求量很大。隨著人們對微創癌症檢測方法的日益偏好，更具創新性和效率的檢測方法正在更快地開發。

政府旨在改善癌症檢測和治療管理的措施也大大促進了市場的成長。液態切片產品可透過各種通路廣泛獲得，包括線上平台和零售店，確保更廣泛的覆蓋範圍和改善歐洲消費者的獲取。這些綜合因素正在推動歐洲液態切片市場的發展，並支持向更有效率、更容易獲得的癌症檢測解決方案的轉變。

隨著非侵入性診斷技術徹底改變了癌症監測和檢測，歐洲液態切片市場正在大幅擴張。液態切片可以檢查血液樣本中的循環腫瘤 DNA (ctDNA)、RNA 和外泌體，是傳統切片檢查技術的有力替代方法。液態切片因其能夠提供即時監測、識別早期癌症復發和評估治療效果，在腫瘤學領域越來越受歡迎。

歐洲癌症發生率的不斷上升、對微創診斷技術的需求不斷成長以及研究和臨床試驗的不斷改進是推動該市場成長的一些因素。隨著液態切片技術的進步，它將支持個人化醫療策略，並能夠在更易於治療的階段更早發現癌症。此外，液態切片的應用範圍正在擴大到腫瘤學以外的領域，包括循環系統、神經科和感染疾病。

旨在鼓勵採用最尖端科技和加強癌症診斷的政府計劃和監管支持也在推動歐洲市場的發展。學術界、醫療保健提供者和產業領袖之間的夥伴關係以及不斷增加的研究資金進一步推動了市場的擴張。隨著零售店和網路平台等通路的擴大，液態切片產品越來越廣泛地提供給歐洲各地的患者和醫療保健提供者。

本報告研究了歐洲液態切片市場，提供了市場概況、最終用戶和國家趨勢，以及參與市場的公司概況。

目錄

執行摘要

第1章 市場

• 市場趨勢
• 供應鏈分析：歐洲液態切片市場
• 法律規範
• COVID-19 對歐洲液態切片市場的影響
• 最近推出的產品/服務
• 贖回情況
• 資金籌措方案
• 產品映射分析
• 市場總規模及滲透率
• 歐洲液態切片市場：相關利益者分析 (N=30)
• 政府關於液態切片的舉措
• 市場動態概覽

第2章 區域

• 歐洲

第3章 市場競爭基準化分析與公司概況

• 公司簡介
  • Dxcover Limited
  • F. Hoffmann-La Roche Ltd.
  • GENinCode PLC (Abcodia Ltd.)
  • QIAGEN NV

第4章調查方法

Introduction to Europe Liquid Biopsy Market

The Europe liquid biopsy market, valued at $1.24 billion in 2024, is expected to reach $5.58 billion by 2033, exhibiting a robust CAGR of 18.18% during the forecast period 2024-2033. In Europe, liquid biopsy is a new non-invasive diagnostic technique that is transforming cancer detection and surveillance. This method has the potential to early detect cancer recurrence or evaluate treatment responses, and it provides real-time monitoring with minimal invasiveness. The growing prevalence of cancer, rising research publications, and clinical trials are some of the factors driving the growth of the liquid biopsy market. These factors are creating higher demand for liquid biopsy tests and products. More innovative and efficient tests have been developed more quickly as a result of the growing preference for minimally invasive cancer detection methods.

The market's growth has also been greatly aided by government initiatives aimed at improving cancer detection and treatment management. Because liquid biopsy products are widely accessible through a variety of distribution channels, such as online platforms and retail stores, is enhancing accessibility and ensuring a broader reach to consumers across Europe. These combined factors are helping the liquid biopsy market in Europe gain significant traction, supporting the transition to more efficient and accessible cancer detection solutions.

Market Introduction

The market for liquid biopsies in Europe is expanding significantly as a non-invasive diagnostic technique that is revolutionizing cancer monitoring and detection. A potent substitute for conventional biopsy techniques, liquid biopsy examines blood samples for circulating tumor DNA (ctDNA), RNA, and exosomes. Its use in oncology is being fueled by its capacity to offer real-time monitoring, identify early cancer recurrence, and evaluate the effectiveness of treatment.

The growing incidence of cancer throughout Europe, the growing demand for minimally invasive diagnostic techniques, and continuous improvements in research and clinical trials are some of the factors driving this market's growth. As liquid biopsy technology advances, it supports personalized medicine strategies and allows early cancer detection at more treatable stages. Furthermore, the expansion of liquid biopsy applications extends beyond oncology, including uses in cardiology, neurology, and infectious diseases.

Government programs and regulatory assistance aimed at advancing the adoption of cutting-edge technologies and enhancing cancer diagnostics are also driving the European market. Further propelling market expansion are partnerships between academia, healthcare providers, and industry leaders, as well as increased research funding. The expansion of distribution channels, such as retail stores and internet platforms, is making liquid biopsy products more widely available to patients and healthcare providers throughout Europe.

Market Segmentation:

Segmentation 1: by End User

• Academic and Research Institutions
• Clinical Laboratories
• Pharmaceutical and Biotechnology
• Companies
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe liquid biopsy market has been segmented based on various categories, such as end user and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Dxcover Limited
• F. Hoffmann-La Roche Ltd.
• GENinCode Plc (Abcodia Ltd.)
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Trends
  • 1.1.1 Increasing Product Launches in the Market
  • 1.1.2 Growing Funding by the Key Players in the Market
• 1.2 Supply Chain Analysis: Europe Liquid Biopsy Market
• 1.3 Regulatory Framework
  • 1.3.1 Regulatory Framework in the European Union (EU)
  • 1.3.2 Regulation in Other Countries
• 1.4 COVID-19 Impact on Europe Liquid Biopsy Market
• 1.5 Recently Launched Product/Services
• 1.6 Reimbursement Scenario
• 1.7 Financing Scenario
  • 1.7.1 Key Players Patent Portfolio
  • 1.7.2 Key Players Stratification as per Raised Financing Value
  • 1.7.3 Key Players Financing Analysis (by Company)
• 1.8 Product Mapping Analysis
  • 1.8.1 By Technology
  • 1.8.2 By Sample
  • 1.8.3 By Circulating Biomarker
  • 1.8.4 By Clinical Application
• 1.9 Total Addressable Market and Penetration
• 1.1 Europe Liquid Biopsy Market: Stakeholder Analysis (N=30)
  • 1.10.1 Physicians' Perception
  • 1.10.2 Payer's Perception
  • 1.10.3 Investors' Perception
• 1.11 Liquid Biopsy Government Initiatives
• 1.12 Market Dynamics Overview
  • 1.12.1 Market Drivers
    • 1.12.1.1 Rising Burden of Cancer
    • 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
    • 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
  • 1.12.2 Market Restraints
    • 1.12.2.1 Technical Limitations in Liquid Biopsy
    • 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
  • 1.12.3 Market Opportunities
    • 1.12.3.1 Integration of AI in Liquid Biopsy
    • 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology

2 Regions

• 2.1 Europe
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Test Volume
  • 2.1.5 Market Size and Forecast
    • 2.1.5.1 By End User
  • 2.1.6 Germany
    • 2.1.6.1 Test Volume
    • 2.1.6.2 Market Size and Forecast
      • 2.1.6.2.1 By End User
  • 2.1.7 U.K.
    • 2.1.7.1 Test Volume
    • 2.1.7.2 Market Size and Forecast
      • 2.1.7.2.1 End User
  • 2.1.8 France
    • 2.1.8.1 Test Volume
    • 2.1.8.2 Market Size and Forecast
      • 2.1.8.2.1 By End User
  • 2.1.9 Italy
    • 2.1.9.1 Test Volume
    • 2.1.9.2 Market Size and Forecast
      • 2.1.9.2.1 By End User
  • 2.1.10 Spain
    • 2.1.10.1 Test Volume
    • 2.1.10.2 Market Size and Forecast
      • 2.1.10.2.1 By End User
  • 2.1.11 Rest-of-Europe
    • 2.1.11.1 Test Volume
    • 2.1.11.2 Market Size and Forecast
      • 2.1.11.2.1 By End User

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Dxcover Limited
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View
  • 3.1.2 F. Hoffmann-La Roche Ltd.
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Key Personnel
    • 3.1.2.5 Analyst View
  • 3.1.3 GENinCode PLC (Abcodia Ltd.)
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Key Personnel
    • 3.1.3.5 Analyst View
  • 3.1.4 QIAGEN N.V.
    • 3.1.4.1 Overview
    • 3.1.4.2 Top Products
    • 3.1.4.3 Top Competitors
    • 3.1.4.4 Key Personnel
    • 3.1.4.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Liquid Biopsy Market, $Million, 2024, 2028, and 2033
• Figure 2: Liquid Biopsy Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3: Key Events to Keep Track of in the Liquid Biopsy Market
• Figure 4: Impact of COVID-19 on Liquid Biopsy Market
• Figure 5: Patent Published (by Country), January 2021-May 2024
• Figure 6: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
• Figure 7: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
• Figure 8: Europe Liquid Biopsy Market Scenario, 2023
• Figure 9: Frequently Used Technology in Liquid Biopsy
• Figure 10: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
• Figure 11: Treatment Guidelines for Treatment of Cancer Patients
• Figure 12: Major Challenges Faced While Performing Liquid Biopsy
• Figure 13: Average Cost of Technologies for the Europe Liquid Biopsy Market (N=30 )
• Figure 14: Cost Difference Across Different End Users for the Europe Liquid Biopsy Market
• Figure 15: Key Factors for Determining Reimbursement Possibility for the Europe Liquid Biopsy Market
• Figure 16: Estimated Global Cancer Incidence in 2020 and 2040
• Figure 17: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
• Figure 18: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
• Figure 19: Comparison of Liquid Biopsy vs. Tissue Biopsy
• Figure 20: Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 21: Europe Liquid Biopsy Market, $Million, 2023-2033
• Figure 22: Germany Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 23: Germany Liquid Biopsy Market, $Million, 2023-2033
• Figure 24: U.K. Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 25: U.K. Liquid Biopsy Market, $Million, 2023-2033
• Figure 26: France Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 27: France Liquid Biopsy Market, $Million, 2023-2033
• Figure 28: Italy Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 29: Italy Liquid Biopsy Market, $Million, 2023-2033
• Figure 30: Spain Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 31: Spain Liquid Biopsy Market, $Million, 2023-2033
• Figure 32: Rest-of-Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 33: Data Triangulation
• Figure 34: Top-Down and Bottom-Up Approach
• Figure 35: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Liquid Biopsy Market, Market Opportunities
• Table 3: Product Launches, January 2021-April 2024
• Table 4: Some of the Strategic Funding, January 2022-April 2024
• Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
• Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
• Table 7: Europe Liquid Biopsy Market: Key Players Patent Portfolio
• Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
• Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
• Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
• Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
• Table 12: Government Initiatives for Liquid Biopsies
• Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
• Table 15: Europe Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 16: Germany Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 17: U.K. Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 18: France Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 19: Italy Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 20: Spain Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 21: Rest-of-Europe Liquid Biopsy Market, $Million, 2023-2033
• Table 22: Rest-of-Europe Liquid Biopsy Market (by End User), $Million, 2023-2033